OPTIMAL研究:口服紫杉醇DHP107对比静脉紫杉醇治疗HER2阴性复发或转移性乳腺癌的III期试验
这项多国、多中心、开放标签、随机III期试验评估了口服紫杉醇DHP107对比静脉紫杉醇在HER2阴性复发或转移性乳腺癌患者中的非劣效性,预设非劣效界值为1.33。共549例患者随机分配,DHP107组中位无进展生存期为10.0个月,静脉紫杉醇组为8.5个月(HR 0.869;95%CI 0.707-1.068),达到非劣效性。DHP107安全性可控,支持其作为有效且便捷的替代方案。
要点
- DHP107在HER2阴性复发或转移性乳腺癌中对比静脉紫杉醇达到非劣效性。
- DHP107组中位PFS为10.0个月,静脉紫杉醇组为8.5个月。
- DHP107血液学毒性及胃肠道不良反应较高,静脉紫杉醇神经毒性和过敏反应更常见。
核心结论
- DHP107对比静脉紫杉醇在HER2阴性复发或转移性乳腺癌中显示出非劣效疗效,安全性可控,支持其作为有效且便捷的替代方案。
研究设计与样本
- 多国、多中心、开放标签、随机III期试验,评估DHP107对比静脉紫杉醇的非劣效性,预设非劣效界值为1.33。
- 纳入既往未接受过转移阶段化疗的HER2阴性复发或转移性乳腺癌患者,随机分配至DHP107组277例或静脉紫杉醇组272例,共549例,符合方案集519例。
主要发现
- DHP107组中位无进展生存期为10.0个月,静脉紫杉醇组为8.5个月(HR 0.869;95%CI 0.707-1.068),达到非劣效性。
- DHP107组中位总生存期为32.6个月,静脉紫杉醇组为31.8个月(HR 0.967,95%CI 0.762-1.227)。
- DHP107组中性粒细胞减少、发热性中性粒细胞减少、恶心、腹泻和呕吐发生率较高,静脉紫杉醇组周围神经病变和过敏反应更常见。
- DHP107组无治疗相关死亡,静脉紫杉醇组有1例(0.4%)治疗相关死亡。
- 两组生活质量相当。
关键数值与推荐
- DHP107用法:200 mg/m2口服,每日两次,第1、8、15天给药,28天为一周期。
- 静脉紫杉醇用法:80 mg/m2静脉给药,第1、8、15天给药,28天为一周期。
- 主要终点为研究者评估的符合方案集无进展生存期,非劣效界值为1.33。
临床怎么用
- 对于HER2阴性复发或转移性乳腺癌且未接受过转移阶段化疗的患者,DHP107可作为静脉紫杉醇的有效且便捷的口服替代方案。
- 使用DHP107时需关注中性粒细胞减少、发热性中性粒细胞减少及胃肠道不良反应,使用静脉紫杉醇时需关注周围神经病变和过敏反应。
局限性
- 全文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intravenous (i.v.) paclitaxel (Taxol) requires prolonged infusion and is associated with hypersensitivity reactions and peripheral neuropathy. This study evaluated the efficacy and safety of DHP107, a novel oral formulation of paclitaxel, compared with i.v. paclitaxel in patients with HER2-negative, recurrent, or metastatic breast cancer. PATIENTS AND METHODS: This multinational, multicenter, open-label, randomized phase III trial evaluated the noninferiority of DHP107 compared with i.v. paclitaxel, with a predefined noninferiority margin of 1.33. Eligible patients had recurrent or metastatic breast cancer and had received no prior chemotherapy in the metastatic setting. Patients were randomly assigned to receive either DHP107 (200 mg/m2 orally twice daily on days 1, 8, and 15) or paclitaxel (80 mg/m2 i.v. on days 1, 8, and 15) in a 28-day cycle. The primary endpoint was investigator-assessed progression-free survival (PFS) in the per-protocol set (PPS). Secondary endpoints included independent central review-assessed PFS, overall survival (OS), tumor response, quality of life, and safety. RESULTS: Between January 2018 and December 2023, 549 patients were randomly assigned to receive either DHP107 (n = 277) or paclitaxel (n = 272); 519 patients were included in the PPS. DHP107 demonstrated noninferiority in PFS with a median PFS of 10.0 months compared with 8.5 months for paclitaxel (hazard ratio [HR] 0.869; 95% confidence interval [CI] 0.707-1.068). The median OS was 32.6 months for DHP107 and 31.8 months for paclitaxel (HR 0.967, 95% CI 0.762-1.227). DHP107 was associated with higher rates of neutropenia, febrile neutropenia, nausea, diarrhea, and vomiting, whereas peripheral neuropathy and hypersensitivity reactions were more common with paclitaxel. No treatment-related death occurred in the DHP107 group, and one (0.4%) in the paclitaxel group. Quality of life was comparable between the two groups. CONCLUSIONS: DHP107 demonstrated noninferior efficacy compared with i.v. paclitaxel, with a manageable safety profile, supporting its use as an effective and convenient alternative in HER2-negative breast cancer.
引用
- Xu B, Jeong H, Sun T, et al. OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer. Ann Oncol. 2026. PMID: 41833903. doi:10.1016/j.annonc.2026.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。